相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma
Apurvasena Parikh et al.
LEUKEMIA & LYMPHOMA (2018)
Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin
Manoj S. Chiney et al.
XENOBIOTICA (2018)
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
Jeffrey A. Jones et al.
LANCET ONCOLOGY (2018)
Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects
Tommy T. Cheung et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers
Ahmed Hamed Salem et al.
CLINICAL DRUG INVESTIGATION (2017)
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Kevin J. Freise et al.
CLINICAL PHARMACOKINETICS (2017)
Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites
Hong Liu et al.
DRUG METABOLISM AND DISPOSITION (2017)
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy
Kevin J. Freise et al.
HEMATOLOGICAL ONCOLOGY (2017)
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Ahmed Hamed Salem et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
A NEW BCL-2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST-IN-HUMAN STUDY
S. Le Gouill et al.
HEMATOLOGICAL ONCOLOGY (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model
Kevin J. Freise et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau et al.
BLOOD (2017)
Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients
K. J. Freise et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia
Ahmed Hamed Salem et al.
ANTI-CANCER DRUGS (2017)
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma
Suresh K. Agarwal et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments
Suresh K. Agarwal et al.
CLINICAL THERAPEUTICS (2017)
Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis
Aksana K. Jones et al.
AAPS JOURNAL (2016)
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis
Kevin J. Freise et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor
Ahmed Hamed Salem et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study
Suresh K. Agarwal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
A novel ritonavir paediatric powder formulation is bioequivalent to ritonavir oral solution with a similar food effect
Ahmed Hamed Salem et al.
ANTIVIRAL THERAPY (2015)
Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies
David J. Greenblatt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Concentration effect relationship of CYP3A inhibition by ritonavir in humans
Christine Eichbaum et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Rapid, simultaneous determination of lopinavir and ritonavir in human plasma by stacking protein precipitations and salting-out assisted liquid/liquid extraction, and ultrafast LC-MS/MS
Francis Myasein et al.
ANALYTICA CHIMICA ACTA (2009)
Dose-Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure
A. A. Mathias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects
J Ng et al.
Journal of the International AIDS Society (2008)
HIV infection and lymphoma
K. L. Grogg et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
分享论文
